TuHURA Biosciences Updates 2026 Inducement Equity Plan Details

What Happened
TuHURA Biosciences, Inc. (Nasdaq: HURA) filed an amendment to its Form 8-K on September 17, 2026 (amending the 8-K filed Sept. 16, 2026) to provide additional information about its 2026 Inducement Equity Incentive Plan. The company disclosed that, as of the plan’s adoption date, it has not granted any equity awards under the Inducement Plan and that any grants will be publicly announced in a press release in accordance with Nasdaq Listing Rule 5635(c)(4). The board currently expects awards under the plan to be stock options for new employees, with exercise prices equal to or greater than the closing market price on the grant date. Shares reserved under the plan will not be issued or outstanding unless and until options vest and are exercised.

Key Details

• Amendment filed Sept. 17, 2026 to supplement the 8-K originally filed Sept. 16, 2026.
• No equity awards have been granted under the 2026 Inducement Equity Incentive Plan as of the plan adoption date.
• All grants will be announced by press release in line with Nasdaq Listing Rule 5635(c)(4).
• Board expects grants to be stock options with exercise price ≥ closing price on grant date; reserved shares become outstanding only upon vesting and exercise.

Why It Matters
This filing provides clarity on how TuHURA plans to compensate new hires and how potential dilution will be handled. Because no awards have been granted yet and shares from the plan won’t become outstanding until options are vested and exercised, there is no immediate dilution or change to the share count. Investors should watch for future press releases announcing specific option grants — those announcements will identify recipients, grant sizes, and vesting, and could signal future dilution if and when options are exercised.